Global Human Microbiome Industry Landscape 2021-2028 – New Fecal Microbiota Drug Requirements Offer Opportunities –


DUBLIN – (BUSINESS WIRE)–The Global Human Microbiome Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Product (Probiotics, Food, Prebiotics, Medical Food, Diagnostic Equipment, Drugs, and Dietary Supplements), Disease, and Application “ Report was added to to offer.

The global human microbiome market is projected to reach $ 2,921.68 million by 2028, up from $ 718.95 million in 2021; It is estimated that it will grow at a CAGR of 22.2% over the 2021-2028 period.

Market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advances in metagenomics and next generation sequencing. Strict regulatory requirements and a lack of knowledge of detailed audits, however, are hampering market growth.

Humans coexist with the diverse microbial species that live in and on the surface of their bodies. Recent studies have shown that these microbial communities essentially serve as another organ of the body as they play a crucial role in human physiology and disease progression. Several fundamental and translational research efforts have been initiated to focus on deciphering microbiome function and its benefits for human health. Many human diseases, such as inflammatory bowel disease and obesity, have been closely linked to the composition of the microbial community in the gut; in addition, diseases such as asthma and diabetes are believed to affect this microbial community.

Much effort is being made to alter the gut microbiome to eradicate various diseases. Probiotics, prebiotic supplements, and foods containing live microbes have been thoroughly studied to assess their effects on human health. In addition, several companies design and develop various microbiome therapies. Rebiotix Inc. developed a drug platform for Microbiota Restoration Therapy (MRI) to deliver healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease. Hence, the increasing focus on human microbiome therapies will be the main driver driving the growth of the human microbiome market in the years to come.

Based on the Product, the Human Microbiome market is further divided into Food, Medicinal Food, Probiotics, Prebiotics, Medicines, Diagnostic Equipment, and Dietary Supplements. The market is divided by diseases into diabetes, cancer, autoimmune diseases, obesity, mental disorders, and other diseases. In 2021, the obesity segment is likely to hold the largest market share, while the market for the diabetes segment is expected to grow at the fastest CAGR during the forecast period. The rising prevalence of diabetes and increasing research into the treatment of diabetes are driving the growth of the human microbiome market.

The World Health Organization (WHO), the National Health Service (NHS), the Centers for Disease Control and Prevention (CDC), the Centers for Medicare and Medicaid Services, the American Academy of Dermatology, and corporate websites are major primary and secondary sources on which is referenced in preparing the report on the Human Microbiome Market.

Key issues covered

1 Introduction

1.1 Scope of the study

1.2 Research Report Guidelines

1.3 Market segmentation

2. Global Human Microbiome Market – Key Findings

3. Research methodology

3.1 coverage

3.2 Desk research

3.3 Primary research

4. Human Microbiome Market – Market Landscape

4.1 Overview

4.1.1 North America – PEST Analysis

4.1.2 Europe – PEST analysis

4.1.3 Asia-Pacific PEST Analysis

4.1.4 Middle East and Africa – PEST Analysis

4.1.5 South and Central America – PEST Analysis

4.2 Expert opinions

5. Human Microbiome Market – Key Market Dynamics

5.1 Key market drivers

5.1.1 Increasing incidence of lifestyle diseases

5.1.2 Increasing focus on human microbiome therapies

5.1.3 Growing technological advances in metagenomics and next generation sequencing

5.2 Important Market Restrictions

5.2.1 Strict government guidelines

5.2.2 Lack of knowledge and thorough examination

5.3 Main market opportunities

5.3.1 New drug requirements for fecal microbiota

5.3.2 Emerging Markets

5.4 Future trend

5.4.1 The human microbiome – a new frontier in drug discovery

5.5 Impact analysis

6. Human Microbiome Market – Global Analysis

6.1 Global Sales Forecast and Analysis for Human Microbiome Market

6.2 Global Human Microbiome Market by Geography-Forecast and Analysis

6.3 Market positioning of the main players

7. Human Microbiome Market Analysis – By Product

7.1 Overview

7.2 Revenue Share of the Human Microbiome Market by Product (2021 and 2028)

7.3 Food

7.4 Medical food

7.5 probiotics

7.6 prebiotics

7.7 Medicines

7.8 Diagnostic devices

7.9 Supplements

8. Human Microbiome Market Analysis – By Disease

8.1 Overview

8.2 Human Microbiome Market Revenue Share by Disease (2021 and 2028)

8.3 Diabetes

8.4 Cancer

8.5 Autoimmune Diseases

8.6 obesity

8.7 Mental disorders

8.8 Other

9. Human Microbiome Market Analysis – By Application

9.1 Overview

9.2 Revenue Share of the Human Microbiome Market by Application (2021 and 2028)

9.3 Therapeutics

9.4 Diagnosis

10. Global Human Microbiome Market – Geographical Analysis

10.1 North America: Human Microbiome Market

10.2 Europe: Human Microbiome Market Revenue and Forecasts to 2028

10.3 Asia Pacific: Human Microbiome Market

10.4 Middle East and Africa: Human Microbiome Market

10.5 South and Central America: Human Microbiome Market

11. Impact of the COVID-19 Pandemic on the Human Microbiome Market

11.1 North America: Impact Assessment of the COVID-19 Pandemic

11.2 Europe: Impact assessment of the COVID-19 pandemic

11.3 Asia-Pacific: Impact Assessment of the COVID-19 Pandemic

11.4 Middle East and Africa: Impact Assessment of the COVID-19 Pandemic

11.5 South and Central America: Impact Assessment of the COVID-19 Pandemic

12. Industry landscape

12.1 Overview

12.2 Growth strategies of companies in the market, (%)

12.3 Organic Developments

12.4 Inorganic Developments

13. Company profiles

13.1 MaaT-Pharma


13.3 AOBiome

13.4 Kaleido Biosciences, Inc.

13.5 Seres Therapeutics

13.6 Merck & Co. Inc.

13.7 Yakult Honsha Co. Ltd.

13.8 Rebiotix, Inc.

13.9 DuPont de Nemours, Inc.

13.10 Synthetic Biologics, Inc.

For more information on this report, see


Comments are closed.